All In Biotech

Drug Trial Radar · NCT03597399

A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US

A Post-Authorization, Multicenter, Longitudinal, Observational Safety Registry Study for Patients Treated With Voretigene Neparvovec in US

Last checked: Nov 20, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

87

Actual

Start

Jan 10, 2019

Primary completion

Jun 30, 2025

Study completion Jun 30, 2025

Sponsor

Lead sponsor
Spark Therapeutics, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 24, 2018

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to collect long-term safety information (i.e., for 5 years after treatment) associated with voretigene neparvovec-rzyl (vector and/or transgene), its subretinal injection procedure, the concomitant use of corticosteroids, or a combination of these procedures and products. The enrollment period will last for two years from the first treatment following product approval (through 31March2020) and include a minimum of 40 patients.

Conditions

  • Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy

Interventions

  • AAV2-hRPE65v2,voretigene neparvovec-rzylBiological

    Subretinal administration of gene therapy vector AAV2-hRPE65v2 (voretigene neparvovec-rzyl) to both eyes via surgical procedures on separate days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Collection of all Adverse Events and Serious Adverse EventsTime frame: up to 5 years

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital of Los Angeles

    Los Angeles, California

  • Bascom Palmer Eye Institute

    Miami, Florida

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa

  • Massachusetts Eye and Ear Institute

    Boston, Massachusetts

  • Kellogg Eye Center

    Ann Arbor, Michigan

  • Cincinnati Eye Institute

    Cincinnati, Ohio

  • Casey Eye Institute

    Portland, Oregon

  • Children's Hospital of Philadelphia (CHOP)

    Philadelphia, Pennsylvania

  • Scheie Eye Institute

    Philadelphia, Pennsylvania

  • Cullen Eye Institute

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.